GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Zenotech Laboratories Ltd

Zenotech Laboratories Reports Q2 FY27 Net Loss of Rs. 257.33 Lakhs

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 28 Oct 2026, 02:26 PM IST  ·  BSE ID: 54ce31d3-7e08-4370-a151-10c033488606
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a net loss of Rs. 257.33 Lakhs for the latest quarter, with revenue at Rs. 613.15 Lakhs.
🤖 AI Summary
  • Zenotech Laboratories reported a standalone Net Loss of Rs. 257.33 Lakhs for the quarter ended September 30, 2026.
  • Total Income for Q2 FY27 was Rs. 757.15 Lakhs, with Revenue from Operations at Rs. 613.15 Lakhs.
  • The half-year ended September 30, 2026, registered a Net Loss of Rs. 302.88 Lakhs.
  • The Board of Directors approved the unaudited standalone financial results, including the Limited Review Report.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Net Profit/(Loss) for the period (Q2 FY27)
(257.33) Rs in Lakhs
Not comparable — limited prior period data.
Revenue from operations (Q2 FY27)
613.15 Rs in Lakhs
Not comparable — limited prior period data.
Total Income (Q2 FY27)
757.15 Rs in Lakhs
Not comparable — limited prior period data.
Net Profit/(Loss) for the half-year (H1 FY27)
(302.88) Rs in Lakhs
Not comparable — limited prior period data.
🏢 How This Affects the Company
💰
Financial Impact
The company recorded a Net Loss of Rs. 257.33 Lakhs for Q2 FY27 and a half-year Net Loss of Rs. 302.88 Lakhs, impacting overall profitability. Total Assets decreased to Rs. 10,987.56 Lakhs from Rs. 11,115.35 Lakhs as of March 31, 2026.
⚠️
Risk Impact
The continued losses in Q2 FY27 and for the half-year increase financial risk. The negative Profit/Loss before tax of Rs. (342.09) Lakhs indicates challenges in core operations before tax considerations.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as the reported net losses impact overall equity. Total equity decreased to Rs. 9,212.35 Lakhs from Rs. 9,512.11 Lakhs as of March 31, 2026.
🔍
Management Signal
The approval of the unaudited financial results signals management's adherence to regulatory disclosure requirements regarding financial performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — observe trends in revenue and profitability.
Any updates on operational strategies to address current losses.
Changes in employee benefit expenses or other expenses in subsequent quarters.
HIGH RISK The company reported consecutive net losses, indicating ongoing financial challenges.
💡 Investor Takeaway
Zenotech Laboratories recorded a standalone Net Loss of Rs. 257.33 Lakhs for Q2 FY27, compared to a Net Loss of Rs. 83.65 Lakhs in Q2 FY26. Half-year Net Loss was Rs. 302.88 Lakhs, versus a Net Profit of Rs. 15.30 Lakhs in H1 FY26.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Zenotech Laboratories reported a Net Loss of Rs. (257.33) Lakhs for the quarter ended September 30, 2026.
  • The company's Revenue from operations decreased to Rs. 613.15 Lakhs in Q2 FY27 from Rs. 1,023.19 Lakhs in Q2 FY26.
📅 Company Track Record
Zenotech Laboratories reported a Net Loss of Rs. 257.33 Lakhs in Q2 FY27, following a Q1 FY27 Net Loss of Rs. 45.55 Lakhs. For the full FY26, the company recorded a net loss of Rs. 107.21 Lakhs, a reversal from a profit of Rs. 561.29 Lakhs in the prior year.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Zenotech Laboratories' net profit/loss for Q2 FY27?
Zenotech Laboratories reported a standalone Net Loss of Rs. (257.33) Lakhs for the quarter ended September 30, 2026.
What was Zenotech Laboratories' revenue from operations in Q2 FY27?
Revenue from operations for Zenotech Laboratories stood at Rs. 613.15 Lakhs for the quarter ended September 30, 2026.
What was Zenotech Laboratories' net profit/loss for the half-year ended September 30, 2026?
Zenotech Laboratories recorded a standalone Net Loss of Rs. (302.88) Lakhs for the half-year ended September 30, 2026.
How did Zenotech Laboratories' total expenses change in Q2 FY27?
Total expenses for Zenotech Laboratories were Rs. 1,099.24 Lakhs for the quarter ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.